🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Phibro Animal Health Corporation PAHC R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.pahc.com

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

READ MORE ›
$30.79
+27.76% 1Y

Market & Price

Market Cap
$1.25B
Current Price
$30.79
High / Low (52W)
$59.58 / $23.68
Beta
0.61

Valuation

Stock P/E
13.21
Industry PE
23.65
Forward P/E
9.21
PEG Ratio
1.68
Book Value
$8.92
Price to Book
3.45
P/S
0.83
EV/EBITDA
8.35
Dividend Yield
1.56%

Profitability & Returns

ROCE
9.48%
ROE
30.34%
ROA
8.40%
Profit Margin
6.35%
Op Margin
12.56%
EPS (Latest Qtr)
$0.59
EPS (TTM)
$2.33

Balance Sheet & Liquidity

Debt/Equity
2.18
Quick Ratio
1.06
Current Ratio
3.17
Debt
$788.68M
Total Assets
$1.36B
Current Assets
$810.61M
Working Capital
$517.13M

Ownership

Promoter Holding
0.80%
Chg in Prom Hold
-
FII / Inst Holding
99.46%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$1.96B
Total Revenue (TTM)
$1.50B
EBITDA
$234.75M
Free Cash Flow
$-17.68M
Operating Cash Flow
$66.13M
Shares Outstanding
21.07M
Gross Margin
32.57%
Payout Ratio
20.60%

Growth (CAGR)

Revenue 5Y
11.22%
Profit 5Y
-0.62%
Revenue (YoY)
10.30%
Earnings (YoY)
15.70%

PROS

  • Strong return on equity of 30.3%.
  • Compounding revenue at 11.2% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -0.6% CAGR over 5 years.
  • Trading 48.3% below its 52-week high.
  • RSI at 23 suggests oversold conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PAHC Phibro Animal Health Corporation R2K 30.79 13.21 $1.25B 1.56% 9.48% 30.34% 11.22% -0.62%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Sep 2016Dec 2016Mar 2017Sep 2017Dec 2017Mar 2018Sep 2018Dec 2018Mar 2019Sep 2019Dec 2019Mar 2020Sep 2020Dec 2020Mar 2021Sep 2021Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------------------214.66M232.71M239.62M232.52M244.65M245.67M231.35M249.94M263.22M260.43M309.26M347.82M378.70M363.89M373.91M383.54M
Cost of Revenue -----------------------------------243.26M268.69M244.11M241.25M257.87M
Gross Profit 52.84M54.27M60.33M56.09M59.11M60.85M59.21M61.46M58.79M61.00M63.50M60.62M63.38M66.92M69.07M65.81M68.64M64.87M57.66M69.10M69.55M64.12M68.27M69.17M64.68M70.67M71.63M68.65M77.39M75.54M67.73M78.62M79.60M83.50M101.87M104.57M110.01M119.78M132.66M125.67M
Operating Expenses -----------------------------------71.05M76.29M68.52M82.33M81.02M
Operating Income 17.32M13.06M25.11M19.79M21.81M20.96M21.86M22.62M21.17M21.81M22.63M29.97M22.39M23.94M26.49M22.85M25.71M22.57M10.15M19.61M21.32M15.69M19.89M20.13M14.61M22.29M19.19M13.68M15.84M18.55M-726.00K15.70M19.92M17.70M25.53M33.52M33.72M51.26M50.33M44.65M
EBITDA -----------------------------------51.38M44.71M61.07M61.16M54.87M
Interest Expense -----------------------------------9.08M8.46M11.97M11.84M10.11M
Pretax Income -----------------------------------29.69M23.85M36.27M36.42M32.31M
Tax Provision -----------------------------------8.81M6.62M9.74M8.97M8.29M
Net Income 6.37M-17.64M18.93M14.25M16.70M10.40M18.75M30.18M18.58M12.18M13.42M23.64M15.89M7.03M19.84M16.31M14.75M14.85M2.52M11.89M13.50M12.30M12.80M12.16M6.53M17.46M17.69M3.86M7.21M10.04M-8.02M1.27M8.40M6.97M3.19M20.88M17.22M26.53M27.46M24.02M
Diluted EPS 0.21-0.480.360.420.260.470.750.460.310.340.590.390.170.490.400.360.370.060.290.330.300.320.300.160.430.440.100.180.25-0.200.030.210.170.080.510.420.650.670.59

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Revenue --------800.35M833.35M942.26M977.89M1.02B1.30B
Cost of Revenue ----------656.86M679.65M704.59M896.27M
Gross Profit 164.14M178.96M204.41M233.28M239.03M248.24M266.88M264.62M256.88M271.38M285.40M298.24M313.09M399.94M
Operating Expenses ----------206.41M226.39M259.78M289.48M
Operating Income 49.33M56.73M63.79M87.67M85.74M97.93M98.93M83.23M69.19M74.87M78.99M71.85M53.31M110.47M
EBITDA ----------117.13M106.03M69.06M146.85M
Interest Expense ----------12.10M17.95M21.97M33.25M
Pretax Income ----------72.33M54.07M10.92M67.99M
Tax Provision ----------23.15M21.46M8.50M19.73M
Net Income 6.98M24.89M-3.13M60.28M82.73M64.61M64.88M54.71M33.55M54.38M49.17M32.61M2.42M48.26M
Diluted EPS -0.82-0.101.512.071.611.611.350.831.341.210.810.061.19
R&D Expense 7.19M6.64M8.21M9.51M11.03M9.44M10.00M12.09M13.74M17.76M20.83M24.39M29.19M23.73M

Compounded Sales Growth

5 Years:11.22%
1 Year:10.30%

Compounded Profit Growth

5 Years:-0.62%
1 Year:15.70%

Stock Price Performance

1 Year:+27.76%
6 Months:-30.19%
3 Months:-43.47%
1 Month:-41.35%

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Assets --474.14M472.32M493.32M607.84M623.40M671.68M726.67M784.10M-931.70M971.40M982.18M1.36B
Current Assets -----------566.23M585.72M601.00M810.61M
Cash & Equivalents 48.60M53.90M27.37M11.82M29.22M33.60M56.08M29.17M57.57M36.34M-74.25M41.28M70.61M68.04M
Inventory -----------259.16M277.57M265.91M444.43M
Receivables -----------166.54M163.48M169.45M227.98M
Total Liabilities --543.08M457.17M463.69M517.36M472.24M486.73M510.66M595.90M-669.26M688.89M725.54M1.08B
Current Liabilities --115.40M112.44M111.33M108.78M115.80M143.22M154.23M157.24M-190.83M176.00M204.15M293.47M
Long Term Debt -----------417.93M452.54M458.29M702.43M
Total Debt -----------470.48M509.97M525.46M761.55M
Total Equity -69.07M-88.23M-68.94M15.15M29.63M90.48M151.16M184.95M216.01M188.20M-262.44M282.51M256.64M285.68M
Shares Outstanding -----------40.50M40.50M40.50M40.53M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Operating Cash Flow ---37.22M98.39M70.01M47.17M59.35M-31.65M13.31M87.59M80.12M
Investing Cash Flow ----82.79M-21.94M-84.61M-14.13M-120.39M--22.58M-74.02M-48.19M-288.69M
Financing Cash Flow ---50.38M-53.74M-11.78M-4.11M40.94M-16.34M26.99M-6.77M207.13M
Capital Expenditure ----------37.04M-51.79M-41.24M-38.29M
Free Cash Flow ----------5.39M-38.48M46.36M41.83M
Net Change in Cash ---------25.41M-33.72M32.63M-1.43M
Dividends Paid 3.00M25.00M15.60M15.71M15.83M16.07M18.59M19.42M19.43M----

Ratios (Annual)

Figures in %.

Metric Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Gross Margin % --------32.1%32.6%30.3%30.5%30.8%30.9%
Operating Margin % --------8.6%9.0%8.4%7.3%5.2%8.5%
Net Margin % --------4.2%6.5%5.2%3.3%0.2%3.7%
ROE % -7.9%-36.1%-20.6%203.5%91.4%42.7%35.1%25.3%17.8%-18.7%11.5%0.9%16.9%
ROCE % -15.8%17.7%23.0%17.2%19.3%18.7%14.5%11.0%-10.7%9.0%6.9%10.3%

Shareholding Pattern

Insiders
0.80%
Institutions
99.46%
Public Float
100.27%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 15.44% 3.25M $100.19M
2 FMR, LLC 10.31% 2.17M $66.91M
3 State Street Corporation 4.51% 950.03K $29.25M
4 Vanguard Capital Management LLC 4.23% 891.28K $27.44M
5 Acadian Asset Management. LLC 2.93% 617.07K $19.00M
6 Geode Capital Management, LLC 2.87% 604.65K $18.62M
7 Renaissance Technologies, LLC 2.74% 576.74K $17.76M
8 Dimensional Fund Advisors LP 2.41% 507.85K $15.64M
9 Vanguard Portfolio Management LLC 2.33% 490.34K $15.10M
10 Nuveen, LLC 2.16% 455.89K $14.04M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PAHC

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks